Author:
Baldwin David S.,Loft Henrik,Dragheim Marianne
Subject
Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology
Reference26 articles.
1. Prevention of relapse in generalised anxiety disorder by escitalopram treatment;Allgulander;Int. J. Neuropsychopharmacol.,2006
2. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder;Alvarez;Int. J. Neuropsychopharmacol,2011
3. Diagnostic and Statistical Manual of Mental Disorders;American Psychiatric Association (APA),2000
4. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder;Bang-Andersen;J. Med. Chem.,2011
5. Assessment of the CYP2C19 interaction potential of Lu AA21004;Buchbjerg;J. Clin. Pharmacol.,2009
Cited by
131 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献